ELITE II and Val-HeFT are different trials: together what do they tell us?

The Losartan Heart Failure Survival Study (ELITE II) and the Valsartan Heart Failure Trial (Val-HeFT) both evaluated the efficacy and tolerability of a selective angiotensin II receptor antagonist on morbidity and mortality in patients with symptomatic heart failure. The trials differed, however, in...

Descripción completa

Detalles Bibliográficos
Autor principal: Dickstein, Kenneth
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2001
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59523/
https://www.ncbi.nlm.nih.gov/pubmed/11806803
http://dx.doi.org/10.1186/cvm-2-5-240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59523/
https://www.ncbi.nlm.nih.gov/pubmed/11806803
http://dx.doi.org/10.1186/cvm-2-5-240

Ejemplares similares